Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30987048 | 0.87 | THRB (0.36) | NR1H2EPHA2THRBNAMPTKDM4E | |
| SCHEMBL29680713 | 0.84 | NAMPT (0.37) | EPHA2THRBNAMPTKDM4ESMN1; SMN2 | |
| SCHEMBL31299259 | 0.84 | NAMPT (0.37) | EPHA2THRBNAMPTKDM4ESMN1; SMN2 | |
| SCHEMBL30738928 | 0.83 | NR1H2 (0.45) | NR1H2THRBNAMPTKDM4EMAPT | |
| SCHEMBL29579871 | 0.78 | PTPN1 (0.40) | THRBNAMPTKDM4ESMN1; SMN2GAA | |
| SCHEMBL29579140 | 0.78 | PTPN1 (0.40) | THRBNAMPTKDM4ESMN1; SMN2GAA | |
| SCHEMBL16893296 | 0.76 | USP2 (0.40) | NR1H2THRBNAMPTKDM4EMAPT | |
| SCHEMBL3136295 | 0.76 | USP2 (0.40) | NR1H2THRBNAMPTKDM4EMAPT | |
| SCHEMBL3126421 | 0.76 | USP2 (0.40) | NR1H2THRBNAMPTKDM4EMAPT | |
| SCHEMBL30990378 | 0.76 | NR1H2 (0.38) | NR1H2EPHA2THRBNAMPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | INSMED INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4561565-A2 | NOVEL DPP1 INHIBITORS AND USES THEREOF | Insmed Incorporated (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026433-A2 | NOVEL DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | DPP4, DPP3, DPP7 | NR1H2 869/4885EPHA2 3286/4885THRB 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.